{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:18:29Z","timestamp":1794835109323,"version":"4.9.1"},"reference-count":38,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2494943","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T04:05:12Z","timestamp":1745121912000},"page":"625-636","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of perioperative nivolumab\u2009+\u2009neoadjuvant platinum doublet chemotherapy as treatment for resectable non-small cell lung cancer in the United States"],"prefix":"10.1080","volume":"28","author":[{"given":"Benjamin","family":"White","sequence":"first","affiliation":[{"name":"Evidera","place":["Wilmington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mack","family":"Harris","sequence":"additional","affiliation":[{"name":"Evidera","place":["Wilmington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald","family":"Villacorta","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Lawrenceville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Sun","sequence":"additional","affiliation":[{"name":"Evidera","place":["Wilmington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Milev","sequence":"additional","affiliation":[{"name":"Evidera","place":["Wilmington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6410-6865","authenticated-orcid":false,"given":"Stefano","family":"Lucherini","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Uxbridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-020-00407-5"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.0126"},{"key":"e_1_3_5_5_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)) for Non-small Cell Lung Cancer V.3.2025. (C) National Comprehensive Cancer Network Inc 2025. All rights reserved. cited Feb 2025. To view the most recent and complete version of the guideline go online to NCCN.org."},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00051"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-88441-7"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.6204"},{"key":"e_1_3_5_9_1","unstructured":"National Institute for Health and Care Excellence. Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer [TA876]; 2023. cited Nov 22 2024 from https:\/\/www.nice.org.uk\/guidance\/TA876."},{"key":"e_1_3_5_10_1","first-page":"823","volume-title":"NICE Technology Appraisal Guidance","author":"National Institute for Health and Care Excellence","year":"2022","unstructured":"National Institute for Health and Care Excellence. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE Technology Appraisal Guidance 823. 2022."},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3857\/roj.2016.01928"},{"key":"e_1_3_5_14_1","unstructured":"National Institute for Health and Care Excellence. NICE DSU TECHNICAL SUPPORT DOCUMENT 14: SURVIVAL ANALYSIS FOR ECONOMIC EVALUATIONS ALONGSIDE CLINICAL TRIALS \u2013 EXTRAPOLATION WITH PATIENT-LEVEL DATA; 2011. Updated March 2013. [cited 2024 Dec 5]. https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/TSD14-Survival-analysis.updated-March-2013.v2.pdf."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00501-4"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12153"},{"key":"e_1_3_5_17_1","unstructured":"National Institute for Health and Care Excellence. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [TA823]; 2022 [cited 2024 Nov 11]. https:\/\/www.nice.org.uk\/guidance\/ta823"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8010"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311926"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-018-0955-5"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.01.004"},{"key":"e_1_3_5_22_1","unstructured":"US Bureau of Labor Statistics. Databases tables & calculators by subject; 2024 [cited 2024 Nov 22]. https:\/\/www.bls.gov\/data\/#prices."},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.04.035"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.1390"},{"key":"e_1_3_5_25_1","first-page":"S8","volume-title":"J Thorac Oncol","author":"Felip E","year":"2024","unstructured":"Felip E, Wakelee H, Vallieres E. IMpower010 5-y subgroup analysis and relapse patterns: phase 3 study of atezolizumab vs BSC in stage II \u2013 IIIA NSCLC. J Thorac Oncol. 2024;19(10):S8\u2013S9."},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.04.007"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.2221"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.11.002"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.02.002"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.06.007"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62159-5"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308"},{"key":"e_1_3_5_33_1","volume-title":"Medical fees directory 2024 - eBook. Usual, customary and reasonable (UCR) fees","author":"Practice Management Information Corporation (PMIC)","unstructured":"Practice Management Information Corporation (PMIC). Medical fees directory 2024 - eBook. Usual, customary and reasonable (UCR) fees. HCUPnet."},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/pmr.2020.0023"},{"key":"e_1_3_5_35_1","unstructured":"Institute for Clinical and Economic Review. Value assessment framework; 2025. Updated September 25 2023. https:\/\/icer.org\/wp-content\/uploads\/2023\/10\/ICER_2023_VAF_For-Publication_101723.pdf."},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.10-a.s1"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5462"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0311"},{"key":"e_1_3_5_39_1","volume-title":"NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"Dias S","year":"2014","unstructured":"Dias S, Welton NJ, Sutton AJ, et\u00a0al. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: NICE; 2014."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2494943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:58:56Z","timestamp":1776873536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2494943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2494943"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2494943","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}